Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 21 Issue 12, December 2025

Inspired by the Review on p703.

Cover design: Steven Hall

Research Highlights

  • Infused lipid nanoparticles were successfully used to generate CAR-T cells in patients with refractory systemic lupus erythematosus, achieving B cell depletion.

    • Maria Papatriantafyllou
    Research Highlight

    Advertisement

  • Biallelic loss-of-function mutations in PLD4, as identified in five patients with SLE, lead to Toll-like receptor-driven hyperactivation of type I interferon, immune cell expansion and autoimmunity.

    • Jessica McHugh
    Research Highlight
  • In a phase III placebo-controlled trial, the addition of telitacicept to standard therapy led to increased clinical response rates for people with systemic lupus erythematosus.

    • Sarah Onuora
    Research Highlight
  • A new population-based study suggests that sodium–glucose cotransporter-2 (SGLT2) inhibitors — originally developed for glycaemic control — reduce the risk of autoimmune rheumatic diseases.

    • Jessica McHugh
    Research Highlight
Top of page ⤴

News & Views

  • Immune-mediated inflammatory diseases (IMIDs) are associated with cancer risk through mechanisms involving disrupted immune tolerance and dysregulated immune responses. Deng et al. investigated how the timing of IMID diagnosis relative to cancer diagnosis affects patient survival outcomes.

    • Dongxue Wang
    • Jianguang Ji
    News & Views
  • Analysis of regional variations in the epidemiology of rheumatoid arthritis (RA) over the past 40 years indicates that the age-standardized incidence of RA has increased — and is expected to continue rising — while the mortality and morbidity of the disease are decreasing. As a result, the number of years lived with disability and the overall disease burden attributable to RA have increased and are projected to rise further.

    • Axel Finckh
    News & Views
Top of page ⤴

Reviews

Top of page ⤴

Correspondence

Top of page ⤴

Amendments & Corrections

Top of page ⤴

Search

Quick links